Impact of Genomics on Drug Discovery and Clinical Medicine

  • Deepak GuptaEmail author


Variability in a drug response, whether it is a safety or an efficacy concern, can likely be addressed by genetic differences among individuals. Incorporating human or relevant microbial genetic alterations during drug discovery phases has vast implications for a drug to be successful in the long run. Pharmacogenomic studies help in identification of superior target and better lead molecules with much higher chances of success; therefore, minimizing risk of drug failure in early preclinical studies. Applications of these principles continue during preclinical animal model selection to address variability in dose-response studies. Use of pharmacogenomic principles comes with unique challenges; however, it also brings on tremendous opportunities to abate drug attrition at later stages of drug development as illustrated by numerous drug examples. Lessons learned from these drug development studies are then applied to product labeling and the post-marketing comprehension of drug behavior.


Pharmacogenomic principles Drug discovery Animal models Lead Development Preclinical trials Clinical trials Dose-response Regulatory consideration 


  1. 1.
    Sakharkar MK, Sakharkar KR, Pervaiz S (2007) Druggability of human disease genes. Int J Biochem Cell Biol 39(6):1156–1164CrossRefPubMedGoogle Scholar
  2. 2.
    Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):727–730CrossRefPubMedGoogle Scholar
  3. 3.
    Sams-Dodd F (2006) Drug discovery: selecting the optimal approach. Drug Discov Today 11(9–10):465–472CrossRefPubMedGoogle Scholar
  4. 4.
    Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN (2003) Human gene mutation database (HGMD): 2003 update. Hum Mutat 21(6):577–581CrossRefPubMedGoogle Scholar
  5. 5.
    Safran M, Solomon I, Shmueli O, Lapidot M, Shen-Orr S, Adato A, Ben-Dor U, Esterman N, Rosen N, Peter I, Olender T, Chalifa-Caspi V, Lancet D (2002) GeneCards 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics 18(11):1542–1543CrossRefPubMedGoogle Scholar
  6. 6.
    Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2005) Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33(Database issue):D514–D517CrossRefGoogle Scholar
  7. 7.
    Maglott D, Ostell J, Pruitt KD, Tatusova T (2005) Entrez gene: gene-centered information at NCBI. Nucleic Acids Res 33(Database issue):D54–D58CrossRefPubMedGoogle Scholar
  8. 8.
    Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R (2004) The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 91(2):355–358CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43(Database issue):D805–D811CrossRefPubMedGoogle Scholar
  10. 10.
    Surendiran A, Pradhan SC, Adithan C (2008) Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol 40(4):137–143CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
  12. 12.
    Chau SB, Thomas RE (2015) The AmpliChip: a review of its analytic and clinical validity and clinical utility. Curr Drug Saf 10(2):113–124CrossRefPubMedGoogle Scholar
  13. 13.
    de Leon J, Correa JC, Ruano G, Windemuth A, Arranz MJ, Diaz FJ (2008) Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 98(1–3):40–46CrossRefPubMedGoogle Scholar
  14. 14.
    Ruano G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, Windemuth A, de Leon J (2007) Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry 12(5):474–482CrossRefPubMedGoogle Scholar
  15. 15.
    Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR (2011) Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 72(4):458–463CrossRefPubMedGoogle Scholar
  16. 16.
    Burmester JK, Sedova M, Shapero MH, Mansfield E (2010) DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 632:99–124CrossRefPubMedGoogle Scholar
  17. 17.
    Sissung TM, English BC, Venzon D, Figg WD, Deeken JF (2010) Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1):89–103CrossRefPubMedGoogle Scholar
  18. 18.
    Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF (1998) Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8(4):325–333CrossRefPubMedGoogle Scholar
  19. 19.
    Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72(1):76–89CrossRefPubMedGoogle Scholar
  20. 20.
    Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH (2010) The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 103(6):765–771CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Edaye S, Tazoo D, Bohle DS, Georges E (2015) 3-halo Chloroquine derivatives overcome plasmodium falciparum Chloroquine resistance transporter-mediated drug resistance in P. Falciparum. Antimicrob Agents Chemother 59(12):7891–7893CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K, Kapella BK, Chang MA, Kamya MR, Staedke SG, Dorsey G, Rosenthal PJ (2015) Artesunate/Amodiaquine versus Artemether/Lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis 213(7):1134–1142CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382(6593):722–725CrossRefPubMedGoogle Scholar
  24. 24.
    Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Katzenstein T, Dickmeiss E, Gerstoft J, Skinhoj P, Svejgaard A, Nielsen JO, Hofmann B (1997) Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 11(3):305–310CrossRefPubMedGoogle Scholar
  25. 25.
    Westby M, van der Ryst E (2005) CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 16(6):339–354CrossRefPubMedGoogle Scholar
  26. 26.
    U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Tekturna NDA 21–985 approval letter, March 5, 2007. Accessed 18 May 2016
  27. 27.
    Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension. Accessed 02 June 2016
  28. 28.
    Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Investig 105(1):3–7CrossRefPubMedGoogle Scholar
  29. 29.
    Le Gallo M, O’Hara AJ, Rudd ML, Urick ME, Hansen NF, O’Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC, Hieter P, Mullikin JC, Merino MJ, Bell DW (2012) Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 44(12):1310–1315CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria. Accessed 02 June 2016
  31. 31.
    Rodriguez-Vicente AE, Lumbreras E, Hernandez JM, Martin M, Calles A, Otin CL, Algarra SM, Paez D, Taron M (2016) Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metab Pers Ther 31(1):25–34PubMedGoogle Scholar
  32. 32.
    Flack JM, Mensah GA, Ferrario CM (2000) Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin 16(2):66–79CrossRefPubMedGoogle Scholar
  33. 33.
    Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13):2825–2831PubMedGoogle Scholar
  34. 34.
    List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Accessed 02 June 2016
  35. 35.
    Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, Klein T, Luzzatto L (2014) Clinical Pharmacogenetics implementation consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 96(2):169–174CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, Kesaniemi YA, Faergeman O (2000) The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation 101(12):1366–1371CrossRefPubMedGoogle Scholar
  37. 37.
    Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, Schaefer EJ (1995) Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113(2):157–166CrossRefPubMedGoogle Scholar
  38. 38.
    Pharmacogenomic Biomarkers in Drug Labeling. Accessed 09 June 2016
  39. 39.
    Pacanowski MA, Leptak C, Zineh I (2014) Next-generation medicines: past regulatory experience and considerations for the future. Clin Pharmacol Ther 95(3):247–249CrossRefPubMedGoogle Scholar
  40. 40.
    Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92(4):414–417CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Anderson CD, Biffi A, Greenberg SM, Rosand J (2010) Personalized approaches to clopidogrel therapy: are we there yet? Stroke 41(12):2997–3002CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Eisenstein M (2015) Big data: the power of petabytes. Nature 527(7576):S2–S4CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.School of PharmacyLECOMBradentonUSA

Personalised recommendations